Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial.
Eline H PloumenRosaly A BuitenPaolo ZoccaCarine J M DoggenGillian A J JessurunCarl E SchotborghAriel RoguinPeter W DanseEdouard BenitAdel AminianRutger L AnthonioSamer SomiGerard C M LinssenMarc HartmannMarlies M KokClemens von BirgelenPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)
Two years after treatment with thin-strut DES in this randomized trial, patients treated for acute MI had lower adverse event rates than non-MI patients. Yet, these findings were mainly attributable to between-group differences in patient and lesion characteristics. In patients who underwent PCI for acute MI, both Resolute Onyx and Orsiro showed favorable and similar 2-year outcomes.
Keyphrases
- acute myocardial infarction
- end stage renal disease
- newly diagnosed
- ejection fraction
- liver failure
- prognostic factors
- heart failure
- clinical trial
- phase iii
- emergency department
- left ventricular
- type diabetes
- randomized controlled trial
- coronary artery disease
- acute coronary syndrome
- drug induced
- adipose tissue
- metabolic syndrome
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- patient reported outcomes
- skeletal muscle
- hepatitis b virus
- insulin resistance